Showing results (31-40 of 55) with videos related to
Sort By:
Pageof 6
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|June 11, 2010
[Acute-onset eosinophilic leukemia associated with tumor lysis syndrome after imatinib and steroid pulse therapy]Tomoe Nemoto, Yuriko Saito, Michihide Tokuhira, et al.American Journal of Hematology|October 5, 2006
De novo CD5+ diffuse large B cell lymphoma with basophilia in the peripheral blood: successful treatment with autologous peripheral blood stem cell transplantationMichihide Tokuhira, Reiko Watanabe, Atsushi Iizuka, et al.Leukemia & Lymphoma|August 26, 2017
Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) scoreEriko Sato, Noriyoshi Iriyama, Michihide Tokuhira, et al.Leukemia Research|January 23, 2017
Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: Surveillance of the CML Cooperative Study GroupNoriyoshi Iriyama, Michihide Tokuhira, Tomoiku Takaku, et al.Medical Oncology (Northwood, London, England)|February 15, 2018
Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phaseMichihide Tokuhira, Yuta Kimura, Keiji Sugimoto, et al.Leukemia & Lymphoma|September 8, 2017
Clinicopathologic investigation of methotrexate-induced lymphoproliferative disorders, with a focus on regressionMichihide Tokuhira, Shuntaro Saito, Ayumi Okuyama, et al.Journal of Clinical and Experimental Hematopathology : JCEH|March 24, 2017
The aggressive clinical courses of Hodgkin lymphoma primarily diagnosed as methotrexate-induced non-specific lymphoproliferative disorder in patients with rheumatoid arthritisMichihide Tokuhira, Takayuki Tabayashi, Yuka Tanaka, et al.Oncology Reports|October 4, 2019
Potential role for second‑generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia harboring additional clonal chromosome abnormalities: A retrospective CML Cooperative Study Group analysisMaho Ishikawa, Noriyoshi Iriyama, Michihide Tokuhira, et al.Medical Oncology (Northwood, London, England)|September 9, 2018
Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysisNoriyoshi Iriyama, Kei-Ji Sugimoto, Eriko Sato, et al.Cancer Medicine|October 10, 2020
The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohortEriko Sato, Noriyoshi Iriyama, Michihide Tokuhira, et al.Pageof 6